Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP

Results of the head-to-head comparison of Pfizer's Lipitor and Bristol-Myers Squibb's Pravachol may reduce industry's enthusiasm for comparative studies, AARP CEO Bill Novelli said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet